Projects

Coordinator: Cristina Fornaguera (Universitat Ramon Llull)

Co-Principal Investigator: Núria de la Iglesia

ViroSTOP will identify targets and repurposed drugs while establishing a universal platform to test therapies for emergent viruses key to promote science-based solutions for outbreak and pandemic prevention.

Principal investigador(s): Oriol Mitjà (Fundació Lluita contra les Infeccions, coordinator), Jorge Carrillo (IrsiCaixa, Principal Investigator), Lorenzo Giacani (University of Washington, Principal Investigator), Wujian (Guangzhou Dermatology Hospital, Principal Investigator)

The project "Revolutionizing pancreatic cancer therapy: validating virus-like particles (VLPs) for neoantigen-based vaccination" focuses on developing a novel immunotherapy strategy for pancreatic cancer through vaccines based on virus-like particles (VLPs). These particles, loaded with specific neoantigens derived from KRAS gene mutations, aim to generate a powerful immune response to delay tumor growth in preclinical mouse models. Additionally, the project will explore regulatory feasibility to advance towards clinical trials in humans.

The project "Validation of virus-like particles as a vaccine platform against pancreatic cancer" develops a novel immunotherapy strategy based on neoantigen vaccines. These vaccines are constructed using virus-like particles (VLPs) that incorporate pancreatic cancer neoantigens to activate a specific immune response against the tumor. The goal is to validate their efficacy in both in vivo and ex vivo preclinical models, as well as to establish the foundations for their future clinical application by exploring regulatory aspects and patentability.